Whereas Congress, by enacting the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 301 et seq. ), authorized the Food and Drug Administration (referred to in this preamble as the FDA ) to determine, based on the scientific expertise of the FDA, whether a drug is safe and effective for the intended use of the drug; Whereas mifepristone is a medication that can be used to terminate a pregnancy; Whereas mifepristone received approval from the FDA more than 20 years ago, and according to the FDA, the efficacy and safety [of mifepristone] have become well-established by both research and experience, and serious complications have proven to be extremely rare ; Whereas the FDA approved mifepristone following a rigorous 54-month review period that included the review of 3 complete phases of clinical trials that involved thousands of participants and whose data showed that mifepristone was safe and effective for termination of an early pregnancy; Whereas, in January 2023, after extensive evidence-based review, the FDA approved a modification to the Mifepristone Risk Evaluation and Mitigation Strategy that removed the in-person dispensing requirement and added a pharmacy certification requirement, allowing Mifeprex and its approved generic mifepristone, Mifepristone Tablets, 200mg, to be dispensed by certified pharmacies, both in-person and by mail, as well as by or under the supervision of certified prescribers; Whereas the FDA relied on overwhelming evidence that medication abortion using mifepristone is a safe and effective method to end a pregnancy; Whereas leading medical and scientific organizations, including the World Health Organization, the American Medical Association, the American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians, recognize that mifepristone is safe and effective and continue to recommend the availability of mifepristone for use in obstetric care